55th Clinical Diabetes & Endocrinology Institute Annual CME Conference

55th Clinical Diabetes & Endocrinology Institute (CDEI) Annual CME Conference is organized by Clinical Diabetes and Endocrinology Institute (CDEI) and will be held from Jan 12 - 15, 2019 at The Westin Snowmass Resort, Snowmass, Colorado, United States of America.

The target audience for this medical event is Endocrinologists, primary care physicians, and other healthcare professionals with an interest in diabetes, endocrinology, and metabolism. This CME Conference has been approved for a maximum of 18 AMA PRA Category 1 Credits.

Why Attend:
The 55th Clinical Diabetes and Endocrinology Institute Annual CME Conference will address gender affirming hormone therapy, gestational diabetes, precision medicine for thyroid tumors, Cushing’s disease, neuroendocrine diseases, obesity therapies, the new ADA/EASD guidelines for type 2 diabetes management, menopause, diabetes technologies, and much more.

Learning Objectives:
• Recognize the clinical manifestations of Cushing's syndrome and data regarding Multiple Endocrine 
  Neoplasia, and assess available interventions in the management and treatment of the disease
• Explain recent guidelines for managing hypopituitarism
• Describe existing and new approaches to managing patients with hyperthyroidism
• Describe applications of precision medicine for patients with thyroid tumors 
• Discuss approaches to managing thyroid disorders in pregnancy 
• Summarize the latest guidelines and best practices for classification, evaluation and management of diabetes, and review the role of technology in managing the disease
• Name the benefits and risks of different pharmacological therapies in management of diabetes in patients with varying comorbidities and risk profiles
• Discuss misinformation about endocrine disorders and the impact on patient care 
• Compare and contrast mefformin, glyburide, and insulin therapy as treatment options for gestational diabetes
• Review options for managing menopause, and evaluate findings from longitudinal studies in women's health 
• Indicate methods for evaluating and managing hormone therapy in transgender patients, including the specific role of the endocrinologist
• Describe characteristics of metabolic bone disease that differentiate it from osteoporosis
• Differentiate between the available evidence for management of primary hyperparathyroidism
• Summarize approaches for addressing weight management in obese patients with comorbid conditions, including pharmacologic and surgical approaches
• Name best practices for evaluation of ASCVD risk and strategies for managing hypercholesterolemia,hypertriglyceridemia, and atherogenic dyslipidemia

Additional details will be posted as soon as they are available.